Polymorphisms in genes involved in the mechanism of action of methotrexate: are they associated with outcome in rheumatoid arthritis patients?

被引：0

作者：

Salazar, Juliana ^{[1
,2
]}

Moya, Patricia ^{[3
,4
]}

Altes, Albert ^{[5
]}

Diaz-Torne, Cesar ^{[3
]}

Casademont, Jordi ^{[3
]}

Cerda-Gabaroi, Dacia ^{[6
]}

Corominas, Hector ^{[6
]}

Baiget, Montserrat ^{[1
,2
]}

机构：

[1] Hosp Santa Creu & Sant Pau, Dept Genet, Barcelona 08025, Spain

[2] CIBERER, U705, Barcelona, Spain

[3] Hosp Santa Creu & Sant Pau, Internal Med Dept, Barcelona 08025, Spain

[4] Univ Autonoma Barcelona, E-08193 Barcelona, Spain

[5] Fundacio Althaia, Hematol Dept, Barcelona, Spain

[6] Hosp Moises Broggi, Rheumatol Dept, Barcelona, Spain

来源：

PHARMACOGENOMICS | 2014年 / 15卷 / 08期

关键词：

5-aminoimidazole-4-carboxamide ribonucleotide transformylase; 5,10-methylenetetrahydrofolate reductase; ATIC; DHFR; dihydrofolate reductase; methotrexate; MTHFR; rheumatoid arthritis; CLINICAL PHARMACOGENETIC MODEL; FUNCTIONAL-ANALYSIS; EFFICACY; RECOMMENDATIONS; MONOTHERAPY; MANAGEMENT; TOXICITY; PREDICT;

D O I：

10.2217/PGS.14.67

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Background: Methotrexate (MTX) is the first-line treatment option for newly diagnosed rheumatoid arthritis (RA) patients. However, 50-70% of the patients respond to treatment and 30% suffer toxicity. Aim: To identify pharmacogenetic markers of outcome in RA patients treated with MTX. Patients & methods: We analyzed 27 genetic variants in DHFR, TYMS, MTHFR, ATIC and CCND1 genes. Results: We included 124 RA patients treated with MTX monotherapy. In multivariate analyses two variants in the MTHFR gene were associated with response, rs17421511 (p = 0.024) and rs1476413 (p = 0.0086), as well as one in the DHFR gene, rs1643650 (p = 0.026). The ATIC rs16853826 variant was associated with toxicity (p = 0.039). Conclusion: MTHFR, DHFR and ATIC genetic variants can be considered as pharmacogenetic markers of outcome in RA patients under MTX monotherapy.

引用

页码：1079 / 1090

页数：12

共 29 条

[1] Albrecht K, 2010, CLIN EXP RHEUMATOL, V28, pS95
[2] Aletaha D, 2005, CLIN EXP RHEUMATOL, V23, pS100
[3] The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD courses
Aletaha, D
Smolen, JS
[J]. RHEUMATOLOGY, 2002, 41 (12) : 1367 - 1374
[4] Annotation of functional variation in personal genomes using RegulomeDB
Boyle, Alan P.
Hong, Eurie L.
Hariharan, Manoj
Cheng, Yong
Schaub, Marc A.
Kasowski, Maya
Karczewski, Konrad J.
Park, Julie
Hitz, Benjamin C.
Weng, Shuai
Cherry, J. Michael
Snyder, Michael
[J]. GENOME RESEARCH, 2012, 22 (09) : 1790 - 1797
[5] EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)
Combe, B.
Landewe, R.
Lukas, C.
Bolosiu, H. D.
Breedveld, F.
Dougados, M.
Emery, P.
Ferraccioli, G.
Hazes, J. M. W.
Klareskog, L.
Machold, K.
Martin-Mola, E.
Nielsen, H.
Silman, A.
Smolen, J.
Yazici, H.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (01) : 34 - 45
[6] THE ANTIINFLAMMATORY MECHANISM OF METHOTREXATE - INCREASED ADENOSINE RELEASE AT INFLAMED SITES DIMINISHES LEUKOCYTE ACCUMULATION IN AN IN-VIVO MODEL OF INFLAMMATION
CRONSTEIN, BN
NAIME, D
OSTAD, E
[J]. JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (06) : 2675 - 2682
[7] DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL
Dulucq, Stephanie
St-Onge, Genevieve
Gagne, Vincent
Ansari, Marc
Sinnett, Daniel
Labuda, Damian
Moghrabi, Albert
Krajinovic, Maja
[J]. BLOOD, 2008, 111 (07) : 3692 - 3700
[8] Fransen J, 2005, CLIN EXP RHEUMATOL, V23, pS93
[9] Fransen J, 2012, PHARMACOGENOMICS, V13, P1087, DOI [10.2217/PGS.12.83, 10.2217/pgs.12.83]
[10] GALIVAN J, 1980, MOL PHARMACOL, V17, P105

← 1 2 3 →